Protocol
09-036
Full Title
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
Purpose
This phase I study will evaluate the safety and effectiveness of different doses of a patient’s own immune cells (T cells) which have been changed to help recognize and destroy his prostate cancer cells by targeting a protein called prostate-specific membrane antigen. The T cells are removed from the patient’s blood, modified with a gene in the laboratory so they are better able to recognize and kill prostate cancer cells, and then returned to the patient’s body. This gene is inserted into the T cells using a weakened virus. /
It is hoped that this approach will help each patient’s own T cells recognize his prostate cancer cells and possibly kill them.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic prostate cancer that has not yet been treated with chemotherapy. Patients may have had hormonal therapy.
- Patients must have rising PSA levels and a serum testosterone level under 50 ng/mL.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Susan F. Slovin at 646-422-4470 or Dr. Howard Scher at 646-422-4330.
Disease(s)
Prostate Cancer
Prostate Cancer: Metastatic Disease after Hormone-Reducing Therapy
Locations
ClinicalTrials.gov
Related Diseases
